title: [Study of the efficacy of cyclosporine used in patients at high risk of keratograft rejection. Communication 1. Results of clinical monitoring].
abstract: The paper presents the results of a long-term (up to 2-year) clinical monitoring of 30 patients operated on for leukomas of various etiology, who were a high risk group and received the oral cyclosporine HEXAL postoperatively. Three types of the course of a postoperative period were identified. These included: an absolutely favorable course in 33.3% of cases (Group 1), a relatively favorable one in 30% (Group 2), and an absolutely unfavorable course in 36.7% (Group 3). The studies demonstrated that cyclosporine diminished the degree of an inflammatory reaction and promotes its rapid relief and better functional results in the late postoperative period. Transparent and semi-transparent engraftment could be achieved in 63.3% of cases. The causes of poor outcomes (in 36.7%) may be the inadequate doses of the cyclosporine and the time of its administration (unsteady-state blood cyclosporine concentrations (TO), the inadequate efficiency or initial inefficiency of immunosuppressive therapy.
authors.forename: P V
authors.initials: PV
authors.lastname: Makarov
authors.forename: T G
authors.initials: TG
authors.lastname: Balaian
authors.forename: O G
authors.initials: OG
authors.lastname: Oganesian
authors.forename: O S
authors.initials: OS
authors.lastname: Slepova
authors.forename: G N
authors.initials: GN
authors.lastname: Bykovskaia
authors.forename: S L
authors.initials: SL
authors.lastname: Iluridze
mesh_terms: D000293:Adolescent; D000328:Adult; D002057:Burns, Chemical / Q000473:pathology / Q000601:surgery; D003315:Cornea / Q000473:pathology*; D065306:Corneal Injuries; D016572:Cyclosporine / Q000627:therapeutic use*; D005126:Eye Burns / Q000139:chemically induced / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome